A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495

PHASE3CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

May 20, 2021

Study Completion Date

May 20, 2021

Conditions
Gastritis
Interventions
DRUG

CKD-495 75mg

CKD-495 75mg Tab.

DRUG

Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg

Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.

DRUG

Placebo of the CKD-495 75mg

Placebo of the CKD-495 75mg Tab.

DRUG

Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg

Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.

Trial Locations (17)

Unknown

Chonnam National University Hospital, Gwangju

Kyoungpook National University Hospital, Daegu

Busan National University Hospital, Busan

Inje University Busan Paik Hospital, Busan

Yeungnam University Medical Center, Daegu

Chonbuk National University Hospital, Jeonju

Seoul National University Bundang Hospital, Seongnam

Chung Ang University Hospital, Seoul

Hanyang University Medical Center, Seoul

Kangbuk Samsung Hospital, Seoul

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Yeouido ST. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT04255589 - A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 | Biotech Hunter | Biotech Hunter